Appraisals - ASAR & FAR
- 31/07/2019
- Appraisal Report: rilpivirine (Edurant) 2936
-
-
- 21/02/2020
- Appraisal Report: ponatinib (Iclusig) 1163
-
-
- 21/04/2020
- Appraisal Report: plerixafor (Mozobil) 3297
-
-
- 17/05/2021
- Appraisal Report: perampanel (Fycompa) 4770
-
-
- 12/10/2021
- Appraisal Report: nitisinone (Orfadin) 2322
-
-
- 21/02/2020
- Appraisal Report: nalmefene (Selincro) 1259
-
-
- 21/02/2020
- Appraisal Report: midodrine (Bramox) 2650
-
-
- 31/07/2019
- Appraisal Report: adalimumab (Humira) 3118
-
-
- 28/08/2020
- Appraisal Report: cefuroxime (Aprokam) 2224
-
-
- 27/06/2019
- Appraisal Report: mepolizumab (Nucala) 3750
-
-
- 01/02/2021
- Appraisal Report: melatonin (Slenyto®) 4694
-
-